Keen On NASDAQ Slot, Concentra Looks To Scupper Jounce And Redx Merger
Mystery Firm Makes Last Minute Bid
In February, Jounce’s future looked bleak after the failure of vopratelimab and fears that its finances would run out. Now, it has two suitors with Concentra making a bid to compete with an all-stock merger with the UK’s Redx.
You may also be interested in...
The UK biotech has teamed up again with Jazz, banking a $10m upfront fee that will help towards advancing its wholly owned ROCK inhibitor program for fibrosis indications.
Vertex and CRISPR look beyond beta thalassemia and sickle cell disease. Also, Bicycle gets $50m up front in Novartis deal, Regeneron commits $75m initially under a Treg collaboration with Sonoma, and Jounce gets a better deal from Concentra to wave off Redx merger.
Gilead has waived its option to acquire Pionyr, allowing the US biotech to explore other partnerships and financing opportunities as it advances a promising pipeline of macrophage-targeting antibodies.